Effects of pentoxifylline on severe intermittent claudication

Area of Science:

• Pharmacology
• Vascular Medicine
• Clinical Trials

Background:

• Intermittent claudication (IC) is a common symptom of peripheral artery disease.
• Limited treatment options exist for severe IC, impacting patient quality of life.
• Pentoxifylline is a hemorheologic agent with potential benefits in circulatory disorders.

Purpose of the Study:

• To evaluate the efficacy of pentoxifylline in patients with severe intermittent claudication.
• To analyze treadmill walking distances in a specific subset of patients with baseline distances under 70 meters.
• To assess treatment effects over a 16-24 week period.

Main Methods:

• Pooled data analysis from a blinded, randomized, multicenter trial.
• Inclusion of patients with severe IC (baseline treadmill distance < 70 m).
• Comparison of pentoxifylline (n=21) versus placebo (n=17) groups.
• Evaluation of initial claudication distance (ICD) and a novel 'minimum distance walked' metric.

Main Results:

• Pentoxifylline showed a 68% improvement in ICD versus 12% for placebo (p=.012).
• The 'minimum distance walked' metric improved by 49% with pentoxifylline versus 3% with placebo (p=.019).
• No significant differences in baseline demographics or walking distances between groups.

Conclusions:

• Pentoxifylline therapy demonstrated significant benefits for patients with severe intermittent claudication.
• The drug effectively improved objective measures of walking capacity in this subset.
• Findings support pentoxifylline as a therapeutic option for severe IC.